With over 25 years of experience in drug development, Dan leads the drug research and development in SEED. She is leading a team to discover E3 ligase for multiple targets by using SEED RITE3TM Platform, develop Protein-Protein Interaction (PPI) assays, perform molecular glue (MG) drug screening, map protein-protein interaction epitopes, evaluate MG drug candidates in vivo and in vitro, and study Mechanism of Action (MOA) of SEED’s drug candidates.
Prior to SEED, Dan led R&D laboratories that developed biologics pipelines for both ImClone Systems and Kadmon Corporation, which were subsequently acquired by Eli Lilly and Sanofi, respectively. At ImClone and Kadmon, Dan oversaw and conducted high-throughput screening (HTS) of phage libraries targeting therapeutic proteins, designed and engineered monoclonal and bispecific antibodies, mapped protein-protein interaction epitopes, and characterized physical properties of proteins and antibodies, in vitro/in vivo efficacies and CMC development of antibody drug candidates. Her work has led to the discovery of multiple therapeutic agents that advanced to clinical trials and received regulatory approval. Dan holds a Master of Science in Biochemistry from the City University of New York (CUNY) in New York, NY, and a Master of Science in Chemistry from Sun Yat-Sen University in Guangzhou, China.